Memorial Sloan Kettering Cancer Center: CAR T-Cell Therapy Proves Effective In First Trial In Patients With Resistant Multiple Myeloma
September 29, 2022
September 29, 2022
NEW YORK, Sept. 29 (TNSres) -- The Memorial Sloan Kettering Cancer Center issued the following news release:
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute, and Roswell Park Comprehensive Cancer Center report in a new study. The patient . . .
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute, and Roswell Park Comprehensive Cancer Center report in a new study. The patient . . .